Status:
UNKNOWN
17-Alpha-Hydroxyprogesterone Caproate in Pregnant Women With Placenta Previa
Lead Sponsor:
Aswan University Hospital
Conditions:
Placenta Previa
Eligibility:
FEMALE
18-45 years
Phase:
NA
Brief Summary
Purpose to evaluate the effects of intramuscular 17-Alpha-Hydroxyprogesterone Caproate (17-OHPC) for prevention of Emergent Cesarean Delivery in symptomatic Pregnant Women with Placenta Previa
Detailed Description
Most authors report an increased risk of bleeding with advancing gestation among women with placenta previa. The American College of Obstetricians and Gynecologists (ACOG) and the Society for Materna...
Eligibility Criteria
Inclusion
- Estimated gestational age: between 24 weeks and 37 week's gestation
- Confirmed Placenta previa; either major or minor degrees.
- Placenta previa with preterm uterine contractions or with a history of at least single attack of mild vaginal bleeding
Exclusion
- Severe attack of bleeding requiring an immediate intervention.
- Fetal heart rates instability or non-reassuring tracing
- Intrauterine fetal death or major fetal anomalies.
- If associated with abruptio placentae
- Patients with known bleeding disorders or on anticoagulant therapy
- Patients with severe medical disorders
Key Trial Info
Start Date :
January 1 2019
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 1 2022
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT03779438
Start Date
January 1 2019
End Date
March 1 2022
Last Update
February 15 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Aswan University
Aswān, Egypt, 81528